arsenic trioxide has been researched along with Myeloproliferative Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, S; Li, WW; Mo, XD; Sui, XF; Wang, CL; Wang, FY; Xu, H | 1 |
| Cassinat, B; Dagher, T; de Thé, H; Edmond, V; Giraudier, S; Kiladjian, JJ; Lallemand-Breitenbach, V; Maslah, N; Niwa-Kawakita, M; Pasquier, F; Plo, I; Vainchenker, W; Verger, E; Villeval, JL | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Foley, SB; Hildenbrand, ZL; Mgbemena, VE; Oravecz-Wilson, KI; Philips, ST; Ross, TS | 1 |
| Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D | 1 |
| Caldas, C; Chin, SF; Cowell, JK; Kasyapa, CS; Kunapuli, P | 1 |
2 review(s) available for arsenic trioxide and Myeloproliferative Disorders
| Article | Year |
|---|---|
Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review.
Topics: Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis | 2022 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
4 other study(ies) available for arsenic trioxide and Myeloproliferative Disorders
| Article | Year |
|---|---|
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Topics: Animals; Arsenic Trioxide; Cell Line; Cell Line, Tumor; Disease Models, Animal; Humans; Interferon-alpha; Janus Kinase 2; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Promyelocytic Leukemia Protein | 2021 |
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2014 |
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Topics: Amino Acid Substitution; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Carrier Proteins; Cell Line; Cell Nucleus Structures; Dimerization; DNA-Binding Proteins; Gene Fusion; Gene Rearrangement; Humans; In Vitro Techniques; Mutagenesis, Site-Directed; Mutant Chimeric Proteins; Myeloproliferative Disorders; Neoplasm Proteins; Nuclear Proteins; Oxides; Plasminogen Activator Inhibitor 2; Promyelocytic Leukemia Protein; Receptor, Fibroblast Growth Factor, Type 1; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins; Two-Hybrid System Techniques; Zinc Fingers | 2006 |